Overall, the results of studies on urological aspects of the metabolic syndrome seem to indicate that BPH and prostate cancer are recently considered as two aspects of the metabolic syndrome, and that an increased insulin level is a common underlying aberration that promotes both BPH and clinical prostate cancer (Nandeesha et al. 2006). Here, INS is linked to benign prostatic hyperplasia.